Hypersensitivity reactions observed w/ abacavir. Patients w/ positive HLA-B*5701 status. Increase in wt & in levels of blood lipids & glucose may occur. Pancreatitis. Risk of virological failure when combined w/ tenofovir disoproxil fumarate as once daily regimen. Monitor patients w/ pre-existing liver dysfunction, including chronic active hepatitis. Patients co-infected w/ chronic HBV or HCV. Acute exacerbation of hepatitis in w/drawal of lamivudine may occur; periodic monitoring of both liver function tests & markers of HBV replication is recommended. Mitochondrial dysfunction in HIV-negative infants exposed in utero
&/or post-natally to nucleoside analogues (zidovudine). Immune reactivation syndrome. Osteonecrosis. Opportunistic infections. MI. Do not take w/ any other medicinal products containing lamivudine or emtricitabine. Combination of lamivudine w/ cladribine is not recommended. Renal & hepatic impairment. Contains azo colouring agent sunset yellow which may cause allergic reactions. Pregnancy & lactation. Childn <25 kg. Elderly.